biologic

Elahere

mirvetuximab soravtansine-gynx

Loss of exclusivityNovember 2034projected — 12-year biologic exclusivity estimate

CompanyImmunoGen, Inc.

Drug detail

Brand name	Elahere
Active ingredient	mirvetuximab soravtansine-gynx
Strength	100MG/20ML (5MG/ML)
Dosage form	Injection
Route	Intravenous
Modality	Biologic
FDA approval	November 2022
Marketing status	Rx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.